Charles Schwab Investment Management Inc. Decreases Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Ultragenyx Pharmaceutical Inc. by 3.3% in the first quarter, owning 593,121 shares valued at approximately $21.5 million.
• Despite the stake reduction, other institutional investors have increased their positions in Ultragenyx, with Federated Hermes Inc. and Point72 Asset Management L.P. both raising their holdings significantly.
• Ultragenyx reported a quarterly revenue of $166.5 million, beating analyst estimates, while its EPS of -$1.17 also surpassed expectations, reflecting a notable growth in revenue of 13.2% compared to the same quarter last year.

Charles Schwab Investment Management Inc. decreased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 593,121 shares of the biopharmaceutical company's stock after selling 20,512 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.63% of Ultragenyx Pharmaceutical worth $21,477,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $57,000. GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $82,000. Quarry LP bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $84,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 231.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 1,911 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

RARE has been the topic of a number of recent research reports. Guggenheim reiterated a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. William Blair initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price on the stock. Cantor Fitzgerald cut their target price on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Finally, Wedbush lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Stock Up 1.8%

NASDAQ RARE traded up $0.52 on Wednesday, reaching $30.08. The company had a trading volume of 1,153,951 shares, compared to its average volume of 1,614,092. The stock has a market capitalization of $2.90 billion, a P/E ratio of -5.44 and a beta of 0.25. The company's fifty day moving average is $31.25 and its 200 day moving average is $35.46. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same period last year, the firm posted ($1.52) EPS. The business's revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.